Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Can-Fite BioPharma Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Can-Fite BioPharma Ltd. - Product Pipeline Review - 2014', provides an overview of the Can-Fite BioPharma Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Can-Fite BioPharma Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Can-Fite BioPharma Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Can-Fite BioPharma Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Can-Fite BioPharma Ltd.'s pipeline products Reasons to buy - Evaluate Can-Fite BioPharma Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Can-Fite BioPharma Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Can-Fite BioPharma Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Can-Fite BioPharma Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Can-Fite BioPharma Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Can-Fite BioPharma Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Can-Fite BioPharma Ltd. Snapshot 4 Can-Fite BioPharma Ltd. Overview 4 Key Information 4 Key Facts 4 Can-Fite BioPharma Ltd. - Research and Development Overview 5 Key Therapeutic Areas 5 Can-Fite BioPharma Ltd. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Can-Fite BioPharma Ltd. - Pipeline Products Glance 10 Can-Fite BioPharma Ltd. - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 Can-Fite BioPharma Ltd. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Can-Fite BioPharma Ltd. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Can-Fite BioPharma Ltd. - Drug Profiles 14 CF-101 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 CF-102 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CF-602 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Can-Fite BioPharma Ltd. - Pipeline Analysis 20 Can-Fite BioPharma Ltd. - Pipeline Products by Target 20 Can-Fite BioPharma Ltd. - Pipeline Products by Route of Administration 21 Can-Fite BioPharma Ltd. - Pipeline Products by Molecule Type 22 Can-Fite BioPharma Ltd. - Pipeline Products by Mechanism of Action 23 Can-Fite BioPharma Ltd. - Recent Pipeline Updates 24 Can-Fite BioPharma Ltd. - Dormant Projects 31 Can-Fite BioPharma Ltd. - Discontinued Pipeline Products 32 Discontinued Pipeline Product Profiles 32 CF-101 32 CF-502 32 Can-Fite BioPharma Ltd. - Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables Can-Fite BioPharma Ltd., Key Information 4 Can-Fite BioPharma Ltd., Key Facts 4 Can-Fite BioPharma Ltd. - Pipeline by Indication, 2014 7 Can-Fite BioPharma Ltd. - Pipeline by Stage of Development, 2014 8 Can-Fite BioPharma Ltd. - Monotherapy Products in Pipeline, 2014 9 Can-Fite BioPharma Ltd. - Phase III, 2014 10 Can-Fite BioPharma Ltd. - Phase II, 2014 11 Can-Fite BioPharma Ltd. - Phase I, 2014 12 Can-Fite BioPharma Ltd. - Preclinical, 2014 13 Can-Fite BioPharma Ltd. - Pipeline by Target, 2014 20 Can-Fite BioPharma Ltd. - Pipeline by Route of Administration, 2014 21 Can-Fite BioPharma Ltd. - Pipeline by Molecule Type, 2014 22 Can-Fite BioPharma Ltd. - Pipeline Products by Mechanism of Action, 2014 23 Can-Fite BioPharma Ltd. - Recent Pipeline Updates, 2014 24 Can-Fite BioPharma Ltd. - Dormant Developmental Projects,2014 31 Can-Fite BioPharma Ltd. - Discontinued Pipeline Products, 2014 32 Can-Fite BioPharma Ltd., Other Locations 33 Can-Fite BioPharma Ltd., Subsidiaries 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.